Kymera Therapeutics (NASDAQ:KYMR) Sets New 12-Month High – Here’s What Happened

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price reached a new 52-week high during trading on Tuesday . The stock traded as high as $105.00 and last traded at $99.45, with a volume of 2891041 shares changing hands. The stock had previously closed at $90.43.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera previously reported quarterly results that beat expectations, with EPS of ($0.71) versus consensus of ($0.89) and revenue of $34.37 million versus estimates of $8.27 million, which supports the bullish long-term thesis.
• Neutral Sentiment: The insider sales were made under pre-arranged Rule 10b5-1 trading plans, which can reduce concern that the transactions reflect a sudden change in outlook.
• Negative Sentiment: Director Bruce Booth sold multiple large blocks of KYMR shares in recent days, including a $24.3 million sale and a $10.5 million sale, which can pressure investor sentiment because of the size and frequency of the transactions. Article Title

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a report on Thursday, February 26th. Jefferies Financial Group initiated coverage on Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Loop Capital set a $97.00 target price on Kymera Therapeutics in a research note on Monday, June 8th. Finally, BTIG Research decreased their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $117.14.

Kymera Therapeutics Price Performance

The company’s fifty day simple moving average is $83.41 and its 200-day simple moving average is $81.31. The firm has a market capitalization of $8.18 billion, a PE ratio of -27.86 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.82) EPS. As a group, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Bruce Booth sold 31,798 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $103.75, for a total transaction of $3,299,042.50. Following the sale, the director owned 613,762 shares in the company, valued at approximately $63,677,807.50. The trade was a 4.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jeremy G. Chadwick sold 4,279 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $81.58, for a total transaction of $349,080.82. Following the transaction, the chief operating officer owned 44,018 shares in the company, valued at approximately $3,590,988.44. This trade represents a 8.86% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 655,603 shares of company stock valued at $60,847,827 in the last 90 days. 15.98% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

Large investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC increased its stake in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after buying an additional 349 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Kymera Therapeutics during the fourth quarter worth $63,000. Osaic Holdings Inc. lifted its stake in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Kymera Therapeutics by 56.3% during the first quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock valued at $107,000 after buying an additional 463 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.